AbbVie Enters Second Vectorised Antibody Partnership with Voyager Therapeutics

By Michelle Liu

Pharma Deals Review: Vol 2019 Issue 3 (Table of Contents)

Published: 8 Mar-2019

DOI: 10.3833/pdr.v2019.i3.2410     ISSN: 1756-7874

Section: Research & Development



In its second multibillion-dollar alliance, Voyager Therapeutics has entered into another collaboration and option agreement with AbbVie to research, develop and commercialise adeno-associated virus and other-virus-based gene therapies for the treatment of Parkinson’s disease and other synucleinopathies...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details